<DOC>
	<DOC>NCT01604278</DOC>
	<brief_summary>This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patients with moderate to severe stable Chronic Obstructive Lung Disease (COPD) Stage II or Stage III according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines. Patients with a postbronchodilator forced expiratory volume in 1 second (FEV1) â‰¥ 30 % and/or &lt;80 % of the predicted normal, and a postbronchodilator FEV1/Forced Vital Capacity (FVC) &lt; 0.70 at screening. Current or exsmokers who have a smoking history of at least 10 pack years Symptomatic patients according to daily diary data. Pregnant or nursing (lactating) women. Women of childbearing potential unless using adequate contraception. Patients with Type I or uncontrolled Type II diabetes. Patients with a history of long time interval between start of Q wave and end of T wave in the heart's electrical cycle (QT) syndrome or whose QT corrected for heart rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged Patients with paroxysmal (e.g. intermittent) atrial fibrillation Patients who have a clinically significant electrocardiogram (ECG) or laboratory abnormality at screening (Visit 2) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>Glycopyrronium Bromide</keyword>
	<keyword>COPD</keyword>
	<keyword>bronchodilation</keyword>
</DOC>